Resistance to BRAF inhibitors is related to reduced cAMP levels in BRAF wild-type and NRAS wild-type melanoma cells and restoring cAMP levels using forskolin (FSK), a cAMP activator, while IBMX, a universal inhibitor of PDEs, sensitizes melanoma cells to BRAF inhibitors [266]. Here, NRAS is linked to melanoma.